Evidence map›Paper›PMID 36430867›Full record

ArticleInternational journal of molecular sciences2022

Developing 3D Organoid Raft Cultures from Patient-Derived Xenografts as Rapid Models to Screen Efficacy of Experimental Therapeutics.

Prachi Bajpai, Nilam Sanjib Banerjee, Dianne W Moore, Hyung-Gyoon Kim, Farrukh Afaq, Carlo M Contreras, Martin J Heslin, Vishnu B Reddy, Shajan Peter, Sooryanarayana Varambally and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Prachi BajpaiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Nilam Sanjib BanerjeeDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-9180-0323
Dianne W MooreDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Hyung-Gyoon KimDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Farrukh AfaqDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Carlo M ContrerasDepartment of Surgery, Ohio State University, Columbus, OH 43210, USA.
Martin J HeslinMitchell Cancer Institute, University of South Alabama, Mobile, AL 36688, USA.
Vishnu B ReddyDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Shajan PeterO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Sooryanarayana VaramballyDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Sameer Al DiffalhaDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-3095-4089
Upender ManneDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
University of Alabama at Birmingham · USThe Ohio State University · USUSA Mitchell Cancer Institute · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
TRAINING AND CAREER DEVELOPMENTU54CA118948 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UPENDER MANNE · 2005 to 2026
$26.6M
Cervical cancer derived xenografts (PDX) and organoid raft cultures to evaluate pathway specific therapeutic agents.R21CA216789 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BANERJEE, NILAM SANJIB · 2019 to 2020
$355k
NCI NIH HHS 5U54CA118948 to UMNCI NIH HHS P30 CA013148NCI NIH HHS R21 CA216789NCI NIH HHS R21 CA216789 to NSBNCI NIH HHS U54 CA118948
6 · The paper itself

Abstract

Reliable preclinical models are needed for screening new cancer drugs. Thus, we developed an improved 3D tumor organoid model termed "organoid raft cultures" (ORCs). Development of ORCs involved culturing tumors ex vivo on collagen beds (boats) with grid supports to maintain their morphological structure. The ORCs were developed from patient-derived xenografts (PDXs) of colon cancers excised from immune-deficient mice (NOD/SCID/IL2Rgamma

Indexed as

NeoplasmsOrganoidsAniline CompoundsAnimalsApoptosis Regulatory Proteinsbcl-X ProteinDisease Models, AnimalHeterograftsHumansMiceMice, Inbred NODMice, SCIDProto-Oncogene Proteins c-bcl-2ShipsSulfonamidesAniline CompoundsApoptosis Regulatory Proteinsbcl-X ProteinnavitoclaxProto-Oncogene Proteins c-bcl-2Sulfonamides3-dimensional (3D) culture modelcolon cancernavitoclax (ABT-263)organoid raft cultures (ORCs)patient-derived xenografts (PDX)

Identifiers

PMID36430867
PMCPMC9698332
OpenAlexW4309738300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.